Paul R. Mouncey, M.Sc ed ., Tiffany M. Osborn, M.D., G. Sarah Power, M.Sc., David A. Harrison, Ph.D., M. Zia Sadique, Ph.D., Richard D. Grieve, Ph.D., Rahi Jahan, B.A., Sheila E. Harvey, Ph.D., Derek Bell, M.D., Julian F. Bion, M.D., Timothy J. Coats, M.D., Mervyn Singer, M.D., J. Duncan Small, D.M., and Kathryn M. Rowan,… Read More

4th International Conference on Bloodstream Treatment and Malignancies OMICS International is pleased to welcome all of the interested individuals to its 4th International Meeting on Blood Malignancies and Treatment during April 18-20, 2016 at Dubai, UAE. The conference will be arranged around the theme ‘Conquering bloodstream cancer with contemporary precision therapeutics and restorative approaches’ uk… Read More

Acorda’s fourth one fourth GAAP net income increases to $12 .7 million Acorda Therapeutics, Inc. today announced its monetary results for the fourth quarter and full year ended December 31, 2011.D., Acorda Therapeutics’ President and CEO. ‘In 2012, we will focus on disciplined, strategic purchase in these areas. We believe there is definitely ample… Read More

3SBio obtains ex-China global legal rights to Apexigen’s anti-TNF mAb technology 3SBio Inc ., , a respected China-based biotechnology company focused on researching, developing, marketing and manufacturing biopharmaceutical products, today announced that it offers acquired the ex-China global rights to Apexigen's anti-TNF monoclonal antibody technology. 3SBio acquired the China rights from Apexigen in 2006… Read More

, a wholly-owned subsidiary of Accellent Holdings Corp., provides entered into an contract to sell its facility located beyond Pittsburgh in Houston just, Pennsylvania to The Perryman Company , also headquartered in Houston, Pennsylvania. Substantially all the Facility’s employees can be employees of Perryman effective upon completion of the sale, which is likely to be… Read More